FDA warns Curaleaf about inflated claims in CBD product marketing

A major medical marijuana company is under fire from the FDA. The agency sent Curaleaf a letter of warning over concerns that the cannabis company is marketing some of its products containing CBD as being effective treatments for cancer, Alzheimer’s disease, opioid withdrawal and pain.